432 related articles for article (PubMed ID: 26826581)
1. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
[TBL] [Abstract][Full Text] [Related]
2. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP
Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180
[TBL] [Abstract][Full Text] [Related]
3. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
4. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
Xi L; Zhang JQ; Liu ZC; Zhang JH; Yan JF; Jin Y; Lin J
Org Biomol Chem; 2013 Jul; 11(26):4367-78. PubMed ID: 23715382
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
[TBL] [Abstract][Full Text] [Related]
7. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
Peng FW; Wu TT; Ren ZW; Xue JY; Shi L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5137-41. PubMed ID: 26475519
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
9. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
11. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
[TBL] [Abstract][Full Text] [Related]
12. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
[TBL] [Abstract][Full Text] [Related]
13. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y
Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044
[TBL] [Abstract][Full Text] [Related]
16. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
17. Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
Zuo SJ; Zhang S; Mao S; Xie XX; Xiao X; Xin MH; Xuan W; He YY; Cao YX; Zhang SQ
Bioorg Med Chem; 2016 Jan; 24(2):179-90. PubMed ID: 26706113
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
